Revolution Medicines, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
RVMD$193.06-3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue: | ||||
| Product revenue, net | $197,559 | $— | $197,559 | $— |
| Total revenue | 197,559 | — | 197,559 | — |
| Costs and expenses: | ||||
| Cost of sales | 327 | — | 327 | — |
| Research and development | 417,087 | 262,506 | 1,155,976 | 692,389 |
| Selling, general and administrative | 153,294 | 52,763 | 364,759 | 128,354 |
| Total costs and expenses | 570,708 | 315,269 | 1,521,062 | 820,743 |
| Loss from operations | (373,149) | (315,269) | (1,323,503) | (820,743) |
| Non-operating income (expense), net: | ||||
| Interest income | 37,779 | 22,083 | 92,866 | 69,402 |
| Interest expense | (33,804) | (11,428) | (69,782) | (12,295) |
| Change in fair value of warrant liability | (40,702) | (592) | (207,521) | (2,731) |
| Other income (expense), net | 66 | — | (57) | (42) |
| Total non-operating income (expense), net | (36,661) | 10,063 | (184,494) | 54,334 |
| Loss before income taxes | (409,810) | (305,206) | (1,507,997) | (766,409) |
| Benefit from income taxes | 2,353 | — | 2,353 | — |
| Net loss | $(407,457) | $(305,206) | $(1,505,644) | $(766,409) |
| Net loss per share attributable to common stockholders, basic and diluted | $(1.90) | $(1.61) | $(7.24) | $(4.06) |
| Weighted-average common shares used to compute net loss per share, basic and diluted | 214,946,012 | 189,231,562 | 208,040,935 | 188,657,560 |
| Comprehensive loss: | ||||
| Net loss | $(407,457) | $(305,206) | $(1,505,644) | $(766,409) |
| Other comprehensive gain (loss): | ||||
| Foreign currency translation adjustments | (95) | — | (196) | — |
| Unrealized gain (loss) on investments, net | (8,624) | 1,814 | (17,710) | 1,795 |
| Comprehensive loss | $(416,176) | $(303,392) | $(1,523,550) | $(764,614) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.